These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8116185)

  • 21. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
    Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
    Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of hepatitis A vaccine (inactivated, non-adsorbed) BRP batches 2 and 3.
    Morgeaux S; Manniam I; Variot P; Buchheit KH; Daas A; Wierer M; Costanzo A
    Pharmeur Bio Sci Notes; 2015; 2015():118-30. PubMed ID: 26830162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consistency as tool to support in vitro batch potency testing in GMP production.
    Stirling C
    Dev Biol (Basel); 2012; 134():115-8. PubMed ID: 22888603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccine (part 2).
    Winsnes R; Sesardic D; Daas A; Behr-Gross ME
    Pharmeuropa Bio; 2006 Nov; 2006(1):73-88. PubMed ID: 17270133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of batch 4 of the Biological Reference Preparation (BRP) for rabies vaccine (inactivated) for veterinary use.
    Daas A; Milne C
    Pharmeuropa Bio; 2004 Dec; 2004(1):17-22. PubMed ID: 15659282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality control of inactivated erysipelas vaccines: results of an international collaborative study to establish a new regulatory test.
    Rosskopf-Streicher U; Johannes S; Wilhelm M; Cussler K
    Vaccine; 2001 Jan; 19(11-12):1477-83. PubMed ID: 11163671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of requirements in the European Union and United States of America for pre-clinical viral safety testing of veterinary vaccines.
    Sheridan S; Coughlin J
    Biologicals; 2010 May; 38(3):340-5. PubMed ID: 20400329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards in vitro potency testing of inactivated erysipelas vaccines.
    Balks E; Wolf C; Loessner H; Werner E
    Dev Biol (Basel); 2012; 134():37-44. PubMed ID: 22888593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rat immunogenicity assay of inactivated poliovirus.
    Bevilacqua JM; Young L; Chiu SW; Sparkes JD; Kreeftenberg JG
    Dev Biol Stand; 1996; 86():121-7. PubMed ID: 8785941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of two serological methods for potency testing of whole cell pertussis vaccines.
    von Hunolstein C; Gomez Miguel MJ; Pezzella C; Scopetti F; Behr-Gross ME; Halder M; Hoffmann S; Levels L; van der Gun J; Hendriksen C
    Pharmeuropa Bio; 2008 Dec; 2008(1):7-18. PubMed ID: 19220977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potency tests of diphtheria, tetanus and combined vaccines. Suggestion for a simplified potency assay.
    Aggerbeck H; Heron I
    Dev Biol Stand; 1996; 86():297-301. PubMed ID: 8785958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potency testing of bacterial vaccines for human use.
    Habig WH
    Vet Microbiol; 1993 Nov; 37(3-4):343-51. PubMed ID: 8116190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ensuring quality of in vitro alternative test methods: Current practice.
    Rispin A; Stitzel K; Harbell J; Klausner M
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):97-103. PubMed ID: 16644076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM workshop 48.
    Bruckner L; Cussler K; Halder M; Barrat J; Castle P; Duchow K; Gatewood DM; Gibert R; Groen J; Knapp B; Levis R; Milne C; Parker S; Stünkel K; Visser N; Volkers P;
    Altern Lab Anim; 2003 Sep; 31(4):429-54. PubMed ID: 15601248
    [No Abstract]   [Full Text] [Related]  

  • 37. Principles of vaccine potency assays.
    Verch T; Trausch JJ; Shank-Retzlaff M
    Bioanalysis; 2018 Feb; 10(3):163-180. PubMed ID: 29333863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory acceptance and use of serology for inactivated veterinary rabies vaccines.
    Schiffelers MJ; Blaauboer BJ; Bakker WE; Hendriksen CF
    ALTEX; 2015; 32(3):211-21. PubMed ID: 25936354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs.
    De Mattia F; Chapsal JM; Descamps J; Halder M; Jarrett N; Kross I; Mortiaux F; Ponsar C; Redhead K; McKelvie J; Hendriksen C
    Biologicals; 2011 Jan; 39(1):59-65. PubMed ID: 21277791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro toxicology industrial platform (IVTIP) position paper, 9 February 2001: the role of an industrial platform in the area of in vitro testing.
    IVTIP Secretariat
    Altern Lab Anim; 2001; 29(4):487-92. PubMed ID: 11506636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.